» Articles » PMID: 38940351

Impact of Obesity‑associated Myeloid‑derived Suppressor Cells on Cancer Risk and Progression (Review)

Abstract

Obesity is a chronic disease caused by the accumulation of excessive adipose tissue. This disorder is characterized by chronic low‑grade inflammation, which promotes the release of proinflammatory mediators, including cytokines, chemokines and leptin. Simultaneously, chronic inflammation can predispose to cancer development, progression and metastasis. Proinflammatory molecules are involved in the recruitment of specific cell populations in the tumor microenvironment. These cell populations include myeloid‑derived suppressor cells (MDSCs), a heterogeneous, immature myeloid population with immunosuppressive abilities. Obesity‑associated MDSCs have been linked with tumor dissemination, progression and poor clinical outcomes. A comprehensive literature review was conducted to assess the impact of obesity‑associated MDSCs on cancer in both preclinical models and oncological patients with obesity. A secondary objective was to examine the key role that leptin, the most important proinflammatory mediator released by adipocytes, plays in MDSC‑driven immunosuppression Finally, an overview is provided of the different therapeutic approaches available to target MDSCs in the context of obesity‑related cancer.

Citing Articles

Myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment and their targeting in cancer therapy.

He S, Zheng L, Qi C Mol Cancer. 2025; 24(1):5.

PMID: 39780248 PMC: 11707952. DOI: 10.1186/s12943-024-02208-3.


Myeloid-Derived Suppressor Cells (MDSCs) and Obesity-Induced Inflammation in Type 2 Diabetes.

Ghemis L, Goriuc A, Minea B, Botnariu G, Martu M, Entuc M Diagnostics (Basel). 2024; 14(21).

PMID: 39518420 PMC: 11544947. DOI: 10.3390/diagnostics14212453.


Post-Kidney Transplant Cancer: A Real-World Retrospective Analysis From a Single Italian Center.

Re Sarto G, Alfieri C, Cosmai L, Brigati E, Campise M, Regalia A Transpl Int. 2024; 37:13220.

PMID: 39228659 PMC: 11368674. DOI: 10.3389/ti.2024.13220.

References
1.
James B, Anderson K, Brincks E, Kucaba T, Norian L, Masopust D . CpG-mediated modulation of MDSC contributes to the efficacy of Ad5-TRAIL therapy against renal cell carcinoma. Cancer Immunol Immunother. 2014; 63(11):1213-27. PMC: 4412276. DOI: 10.1007/s00262-014-1598-8. View

2.
Park J, Han C, Zhao L, Willingham M, Cheng S . Inhibition of STAT3 activity delays obesity-induced thyroid carcinogenesis in a mouse model. Endocr Relat Cancer. 2015; 23(1):53-63. PMC: 4671368. DOI: 10.1530/ERC-15-0417. View

3.
Srikrishna G . S100A8 and S100A9: new insights into their roles in malignancy. J Innate Immun. 2011; 4(1):31-40. PMC: 3250655. DOI: 10.1159/000330095. View

4.
Turbitt W, Collins S, Meng H, Rogers C . Increased Adiposity Enhances the Accumulation of MDSCs in the Tumor Microenvironment and Adipose Tissue of Pancreatic Tumor-Bearing Mice and in Immune Organs of Tumor-Free Hosts. Nutrients. 2019; 11(12). PMC: 6950402. DOI: 10.3390/nu11123012. View

5.
WEISS L, Melchardt T, Habringer S, Boekstegers A, Hufnagl C, Neureiter D . Increased body mass index is associated with improved overall survival in diffuse large B-cell lymphoma. Ann Oncol. 2013; 25(1):171-6. DOI: 10.1093/annonc/mdt481. View